Pharmacology & ToxicologybioRxivPreprint
Sotagliflozin, a dual SGLT1/2 inhibitor, improves cardiac outcomes in a mouse model of early heart failure without diabetes
S. L. Young, L. Ryan, T. P. Mullins…·L. A. Gallo
This study shows that sotagliflozin, a dual SGLT1/2 inhibitor, improves cardiac outcomes in non-diabetic mice with heart failure but not in diabetic mice with proximal tubular damage.
DOI 10.1101/2020.08.15.252593